Clinical Trial 43391

Garden Grove, CA 92845


This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Inclusion Criteria:

  • Patients with a Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of schizophrenia or schizoaffective disorder as confirmed by the Mini International Neuropsychiatric Interview (MINI)
  • Medically stable during the six months prior to study entry
  • Outpatient with no hospitalization for worsening of schizophrenia or schizoaffective disorder within six months prior to study entry
  • PANSS negative symptom factor score of 18 or higher
  • The following rating on items of the PANSS: (a) less than 5 on G8 (uncooperativeness), P1 (delusions), P3 (hallucinations), P4 (excitement/hyperactivity), and P6 (suspiciousness/persecution); (b) less than 4 on P7 (hostility), and G14 (poor impulse control)
  • Has an informant who is considered reliable by the Investigator
  • Part B only: Stable treatment with a dopamine/serotonin (D2/5HT2A) antagonist or a D2 partial agonist for a minimum of 6 months and receiving no more than two antipsychotics

Qualified Participants May Receive:

Monetary compensation and study-related care at no cost to the participant. 

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.